Centrum für Hämatologie und Onkologie am Bethanien-Krankenhaus

Research site

Germany Im Prüfling 17-19, 60389 Frankfurt, Germany

6 trials recruiting
Breast cancer · Breast cancer female · Hormone receptor positive breast cancer
Adult patients

About Specializations

Centrum für Hämatologie und Onkologie am Bethanien-Krankenhaus in Frankfurt, Germany specialises in clinical trials of conditions such as Breast cancer, Breast cancer female, Hormone receptor positive breast cancer, Plasma cell myeloma, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

The medical center is at the forefront of oncology research, with a particular focus on breast cancer. The institution is dedicated to improving outcomes for patients with HER2-negative breast cancer, especially those at high risk of relapse following standard treatments.

HER2-negative breast cancer
Invasive disease-free survival
Neoadjuvant treatment strategies

Through its innovative research, the center is contributing to the development of new therapeutic options, such as sacituzumab govitecan, aimed at enhancing survival rates and quality of life for patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Im Prüfling 17-1960389 FrankfurtGermany

Open in maps ↗

Recruiting now: 6 trials
Conditions studied: 18

More sites in Frankfurt Germany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

14 clinical trials

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo

Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:BeOne Medicines I GmbH

Contact Research Centre

Plasma cell myeloma

Recruiting

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Study of belantamab mafodotin with drug combination in adults aged 18 years and older with relapsed or refractory multiple myeloma

Registered drugNo placebo

Study of belantamab mafodotin with drug combination in adults aged 18 years and older with relapsed or refractory multiple myeloma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Belantamab Mafodotin
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Breast cancer+4

Recruiting

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Elacestrant
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

Study Comparing BGB-16673 to Drug Combinations for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Treated with BTK and BCL2 Inhibitors

Registered drugNo placebo

Study Comparing BGB-16673 to Drug Combinations for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Treated with BTK and BCL2 Inhibitors

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:BGB-16673
Sponsor:BeOne Medicines AG

Contact Research Centre

Plasma cell myeloma

Recruiting

Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo

Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Dexamethasone
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Hormone receptor positive breast cancer

Not recruiting

Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

InvestigationalNo placebo

Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Palbociclib
Sponsor:ABCSG GmbH

Contact Research Centre

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:GBG Forschungs GmbH

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on Abemaciclib and Endocrine Therapy for Patients with Advanced Hormone Receptor Positive HER2 Negative Breast Cancer

Registered drugNo placebo

Study on Abemaciclib and Endocrine Therapy for Patients with Advanced Hormone Receptor Positive HER2 Negative Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:Universitaetsklinikum Ulm AöR

Contact Research Centre

Plasma cell myeloma

Not recruiting

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Breast cancer+3

Not recruiting

Study of Capivasertib and Fulvestrant for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer

Registered drug

Study of Capivasertib and Fulvestrant for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Capivasertib
Sponsor:AstraZeneca AB

Contact Research Centre

Breast cancer+3

Not recruiting

Study on Abemaciclib with Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer at Intermediate to High Risk

Registered drugNo placebo

Study on Abemaciclib with Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer at Intermediate to High Risk

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites